Top

Published in:

01-02-2013 | Original Article

Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer

Authors: Sachi Morita, Keisuke Uehara, Goro Nakayama, Takashi Shibata, Tomoyo Oguri, Megumi Inada-Inoue, Tomoya Shimokata, Mihoko Sugishita, Ayako Mitsuma, Yuichi Ando

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2013

Abstract

Purpose

Bevacizumab, a monoclonal antibody that binds to VEGF, has a well-known toxic effect of hypertension. We studied possible associations between bevacizumab-related hypertension and gene polymorphisms to assure safer cancer therapy.

Methods

We retrospectively studied 60 Japanese patients with metastatic colorectal cancer who had received bevacizumab-based chemotherapy. Genotypes were determined for five well-known functional single-nucleotide polymorphism of the VEGF gene at positions C-2578A, T-1498C, G-1154A, G-634C, and C936T. Hypertension was graded according to CTCAE v4.0 on the basis of home blood pressure.

Results

The VEGF-2578 C/C and -1498 T/T genotypes were associated with significantly less hypertension during the first 2 months of bevacizumab-based chemotherapy (p = 0.004, p = 0.025, respectively). During the treatment period as a whole, the VEGF-2578 C/C and 936 C/C genotypes were associated with less hypertension (p = 0.031, p = 0.043, respectively). Preexisting hypertension was not associated with bevacizumab-related hypertension.

Conclusions

This study demonstrated a significant relation between a lower incidence of grade 2 or higher bevacizumab-related hypertension and the VEGF-2578 C/C genotype for the entire treatment period in Japanese patients with metastatic colorectal cancer. This genotype might be useful for ensuring safer treatment of patients who receive bevacizumab-based chemotherapy.

Jubb AM, Harris AL (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11:1172–1183PubMedCrossRef

Facemire CS, Nixon AB, Grifiths R, Hurwitz H, Coffman TM (2009) Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54:652–658PubMedCrossRef

Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C et al (2009) Arterial hypertension correlates with clinical outcome in cokorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20:227–230PubMedCrossRef

Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ et al (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102:596–604PubMedCrossRef

Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672–4678PubMedCrossRef

Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28:2137–2143PubMedCrossRef

Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH (2010) Clinical course of advanced non-small-cel lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28:949–954PubMedCrossRef

Jain L, Sissung TM, Danesi R, Kohn E, Dahut WL, Kummar S et al (2010) Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 29:95PubMedCrossRef

Stefano AD, Carlomagno C, Pepe S, Bianco R, Placido SD (2011) Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 68:1207–1213PubMedCrossRef

10.

Mohammadi M, Ollier WE, Hutchinson IV (2003) A functional association study of VEGF gene promoter polymorphisms with VEGF expression by stimulated PBM cells. Hum Immunol 64:S125CrossRef

11.

Abajo A, Rodriguez J, Bitarte N, Zarate R, Boni V, Ponz M et al (2010) Dose-finding study and pharmacogenomics analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. B J Cancer 103:1529–1535CrossRef

12.

Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Rec 37:443–448CrossRef

13.

Etienne-Grimaldi MC, Formento P, Degeorges A, Pierga JY, Delva R, Pivot X et al (2010) Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol 71:921–928CrossRef

14.

Ungerback J, Elander N, Dimberg J, Soderkvist P (2009) Analysis of VEGF polymorphisms, tumor expression of VEGF mRNA and colorectal cancer susceptibility in a Swedish population. Mol Med Report 2:435–439PubMed

15.

Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME et al (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Nat Cancer Inst 103:763–773PubMedCrossRef

16.

Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA et al (2008) Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 14:7554–7563PubMedCrossRef

17.

Loupaks F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P et al (2011) Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 11:247CrossRef

18.

Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos F-I, Koumarianou A, Varthalitis I et al (2011) Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-base chemotherapy and bevacizumab. Pharmacogenomics J. doi:10.1038/tpj.2011.37

Title: Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer
Authors: Sachi Morita
Keisuke Uehara
Goro Nakayama
Takashi Shibata
Tomoyo Oguri
Megumi Inada-Inoue
Tomoya Shimokata
Mihoko Sugishita
Ayako Mitsuma
Yuichi Ando
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-012-2028-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2013

Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection

Erratum to: Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation

Amelioration of cisplatin-induced nephrotoxicity in peroxiredoxin I-deficient mice

A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer